Horizon Therapeutics plc
https://www.horizontherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Horizon Therapeutics plc
As Biopharma Seeks Broader IRA Orphan Exclusion, Study Urges Boosting Savings By Eliminating It
Research takes deep dive into the implications around exempting certain orphan drugs that may qualify for the Inflation Reduction Act’s Medicare price negotiation program, including the effect of the exemption on Medicare spending and the revenue potential of those drugs.
Q32 Bio Resets As A Public Company With Two Mid-Stage Assets
The company announced a reverse merger with Homology Medicines that will take the company public while also regaining full rights from Amgen to bempikibart for atopic dermatitis and alopecia areata.
The Biggest M&A Announcements Of 2023 Show Deals Are Getting Bigger
M&A activity in 2023 began with March’s $43bn mega-deal for Seagen, but only one eight-figure takeout has occurred since. Still, the values are higher overall than seen in 2022 and might indicate a gradual return to larger deals.
Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Bio-Technology General Corporation
- Crealta Holdings LLC
- Crealta Pharmaceuticals
- Curzion Pharmaceuticals, Inc.
- Encode Pharmaceuticals, Inc.
- Horizon Pharma plc
- Hyperion Therapeutics, Inc. (Andromeda Biotech Ltd)
- Nitec Pharma AG
- Raptor Pharmaceutical Corp.
- River Vision Development Corp.
- Savient Pharmaceuticals, Inc. (SVNT)
- TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
- Vidara Therapeutics Inc
- Viela Bio, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice